SPRY Relative Valuation
SPRY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SPRY is overvalued; if below, it's undervalued.
Historical Valuation
ARS Pharmaceuticals Inc (SPRY) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -11.54. The fair price of ARS Pharmaceuticals Inc (SPRY) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：9.57
Fair
-6.63
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
ARS Pharmaceuticals Inc. (SPRY) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.34. The thresholds are as follows: Strongly Undervalued below -8.42, Undervalued between -8.42 and -4.88, Fairly Valued between 2.21 and -4.88, Overvalued between 2.21 and 5.75, and Strongly Overvalued above 5.75. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-5.99
EV/EBIT
ARS Pharmaceuticals Inc. (SPRY) has a current EV/EBIT of -5.99. The 5-year average EV/EBIT is -7.64. The thresholds are as follows: Strongly Undervalued below -14.47, Undervalued between -14.47 and -11.05, Fairly Valued between -4.22 and -11.05, Overvalued between -4.22 and -0.81, and Strongly Overvalued above -0.81. The current Forward EV/EBIT of -5.99 falls within the Historic Trend Line -Fairly Valued range.
5.74
PS
ARS Pharmaceuticals Inc. (SPRY) has a current PS of 5.74. The 5-year average PS is 5911.42. The thresholds are as follows: Strongly Undervalued below -33615.86, Undervalued between -33615.86 and -13852.22, Fairly Valued between 25675.06 and -13852.22, Overvalued between 25675.06 and 45438.70, and Strongly Overvalued above 45438.70. The current Forward PS of 5.74 falls within the Historic Trend Line -Fairly Valued range.
-10.87
P/OCF
ARS Pharmaceuticals Inc. (SPRY) has a current P/OCF of -10.87. The 5-year average P/OCF is -11.97. The thresholds are as follows: Strongly Undervalued below -26.20, Undervalued between -26.20 and -19.09, Fairly Valued between -4.85 and -19.09, Overvalued between -4.85 and 2.27, and Strongly Overvalued above 2.27. The current Forward P/OCF of -10.87 falls within the Historic Trend Line -Fairly Valued range.
-8.59
P/FCF
ARS Pharmaceuticals Inc. (SPRY) has a current P/FCF of -8.59. The 5-year average P/FCF is -8.05. The thresholds are as follows: Strongly Undervalued below -22.12, Undervalued between -22.12 and -15.09, Fairly Valued between -1.01 and -15.09, Overvalued between -1.01 and 6.03, and Strongly Overvalued above 6.03. The current Forward P/FCF of -8.59 falls within the Historic Trend Line -Fairly Valued range.
ARS Pharmaceuticals Inc (SPRY) has a current Price-to-Book (P/B) ratio of 6.39. Compared to its 3-year average P/B ratio of 4.16 , the current P/B ratio is approximately 53.55% higher. Relative to its 5-year average P/B ratio of 3.99, the current P/B ratio is about 60.34% higher. ARS Pharmaceuticals Inc (SPRY) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -6.33%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -6.28% , the current FCF yield is about -100.00% lower.
6.67
P/B
Median3y
4.16
Median5y
3.99
-9.11
FCF Yield
Median3y
-6.33
Median5y
-6.28
Competitors Valuation Multiple
The average P/S ratio for SPRY's competitors is 0.00, providing a benchmark for relative valuation. ARS Pharmaceuticals Inc Corp (SPRY) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 1471.62%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SPRY decreased by 5.50% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 2.07M to 32.50M.
The secondary factor is the Margin Expansion, contributed -82.99%to the performance.
Overall, the performance of SPRY in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is ARS Pharmaceuticals Inc (SPRY) currently overvalued or undervalued?
What is ARS Pharmaceuticals Inc (SPRY) fair value?
How does SPRY's valuation metrics compare to the industry average?
What is the current P/B ratio for ARS Pharmaceuticals Inc (SPRY) as of Dec 05 2025?
What is the current FCF Yield for ARS Pharmaceuticals Inc (SPRY) as of Dec 05 2025?
What is the current Forward P/E ratio for ARS Pharmaceuticals Inc (SPRY) as of Dec 05 2025?